"Groupthink" Leads Big Pharma To Downplay Neurosciences At Industry's Peril
Executive Summary
A generation of potentially useful drugs for neurologic disorders may be lost if something isn't done to shore up early stage companies being "strangled fiscally" by the shift in partnering and financing toward later-stage projects, says Harry Tracy, president of NI Research